Generic User Fee Negotiations May Be Falling Behind Schedule
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA and industry look to speed up the talks with GDUFA financial issues still to come.
You may also be interested in...
GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
Negotiations for generic drug user fee reauthorization open with FDA saying it doesn't want a large number of small tweaks that will increase program complexity.
Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire
Clarke helped launch GDUFA I and negotiate GDUFA II, chaired the CDER Executive Committee and oversaw many other programs in the US FDA’s drugs center.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.